Prostate cancer patients normally have a devastatingly short life expectancy - but the new daily pill being offered in clinical trials could change that

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease